7:30 am Welcome Coffee & Registration
8:20 am Chair’s Opening Remarks
Utilise the Advantages of Specific Model Type to Your Research Objectives
8:30 am Preclinical Modelling of Immuno-Oncology Therapies
9:00 am Unique PDX Models to Advance Liquid-Biopsy Research & Immunotherapy
9:30 am Tumour Microenvironment, Heterogeneity & Clinically Relevant Models
10:00 am Assessment of Different Humanised Mouse Models for the Evaluation of Cancer Immunotherapies
10:30 am Speed Networking
11:15 am Morning Refreshments
11:45 am Sophisticated Humanised Mouse Models to Investigate the Mechanisms of Immunotherapy
12:15 pm Panel Discussion – Industry Insight: How to Utilise Complimentary Models to Drive Drug Discovery Development
1:00 pm Lunch and Networking
Apply Complex 3D Models to Support In Vivo Modelling Outcomes
2:00 pm 3D Cancer Stem Cell Models to Study Microenvironment Interactions and Tumour Plasticity
2:30 pm Early In Vivo Identification of Low Value Molecules
3:00 pm Re-Balancing the Suppressive Tumour Environment – Restoring an Effective Immune Response
3:30 pm Q/A Session: Interactive session to uncover more from the latest case studies
3:45 pm Afternoon Break & Networking
4:15 pm Preclinical Profiling of Derazantinib (BAL087), an FGF-R Inhibitor Currently in Phase-2 Clinical Trials
4:45 pm Expertise Insight from Hera Biolabs
5:00 pm Roundtable Discussion
1. Cell Handling, Guidelines & Donor Differential Donor Response
2. Investigating the Potential of Utilising the Microbiome
3. Latest Strategies to Model Tumour Resistance
4. Applying Complex 3D Models to Increase In Vivo Efficacy
1. Cell Handling, Guidelines & Donor Differential Donor Response
• Increasing standardisation in cell handling protocol to enhance reproducibility
• The challenge of tissue heterogeneity in modelling specific immune-responses from patient derived samples
2. Investigating the Potential of Utilising the Microbiome
3. Latest Strategies to Model Tumour Resistance
4. Applying Complex 3D Models to Increase In Vivo Efficacy